Q-omics provides the consensus-scored CAPS profile across patient tissues and cancer cell-line models. CAPS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAPS is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CAPS protein abundance shows 29,163 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, and UCEC as cancer lineages where CAPS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPS survival associations across molecular data types. CAPS RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPS RNA expression–survival associations across cancer types. High CAPS expression shows unfavorable associations in KIRC, ACC, COAD and LGG, but favorable associations in HNSC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAPS RNA expression.
This table summarizes CAPS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CAPS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPS shows lower tumor expression in KIRC, KICH, KIRP, LUSC and LUAD and higher tumor expression in LIHC. The KIRC box plot shows higher CAPS RNA expression in normal versus tumor tissue (log2 FC = −2.343, t-test p < 0.001).
This table shows molecular features associated with CAPS in patient tissues and cancer cell lines. In patient samples, CAPS shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
